HER2 is the most frequently used RTK for CAR-T cell therapy in breast cancer as currently there are 3 HER2-CAR-T cell therapy and 1 multi-targets CAR-T cell therapies under clinical trials (NCT04650451, NCT03740256, NCT03696030, and NCT04430595). The gene discussed is ERBB2; the disease is breast carcinoma.